Sanofi

Sanofi is based in Paris. Dupixent, developed and commercialized with Regeneron, is the atopic dermatitis and asthma antibody that now dominates the company's growth, while Lantus insulin glargine competes with biosimilars such as Lilly's Basaglar.

The vaccine arm supplies influenza vaccines and, with AstraZeneca, the infant RSV antibody Beyfortus. Public health programs and hospital maternity wards place those orders, and GSK, Pfizer, and Merck bid the same seasonal calendars.

Lantus volumes have already shifted as payers prefer cheaper glargine, which is a different fight from Dupixent's prior-authorization rules at dermatology and pulmonology clinics. Regeneron shares Dupixent economics, so the two companies' incentives on price and indication expansion stay linked.

Dupixent coverage depends on prior authorization at pharmacy benefit managers and on new approved indications.

Lantus competes with interchangeable glargine biosimilars on Medicare and commercial insulin formularies.

Seasonal vaccine tenders award a year's doses to one or two suppliers for a whole public program.

A family can meet Sanofi three ways: an insulin pen, a child's vaccine visit, and a Dupixent specialty prescription.

Clinics that stock Beyfortus for a winter season cannot easily switch brands once the campaign has started.